Quest Diagnostics Incorporated · NYSE:DGX

Quest Diagnostics — Investor Day (November 2018)

15 slides from Quest Diagnostics's investor day presentation, Nov 29, 2018

1. Slide 1: Innovation and Growth in Advanced Diagnostics

   Innovation and Growth in Advanced Diagnostics Carrie Eglinton Manner SVP, Advanced Diagnostics

2. Slide 2: Safe Harbor Disclosure

   SAFE HARBOR DISCLOSURE The statements in the following presentations that are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s cur

3. Slide 3: How far we've come

   How far we’ve come 20 years ago This week FDA approves Herceptin for breast FDA approves Vitrakvi for a specific genetic cancer targeted at the tumor’s genetics mutation, not cancer type Source: US National Cancer Institute 3 Confidential | Internal Use Only

4. Slide 4: Leading position in significant growth market

   Leading position in significant growth market $1B+ in Advanced Diagnostics Strong health system-hospital relationships Profitable growth Oncology Women’s Health Infectious Neurology CardioMetabolic Disease Better Access = Stronger Growth 4 Confidential | Internal Use Only

5. Slide 5: Differentiated strengths to generate growth

   Differentiated strengths to generate growth Medical expertise Size and scale for Science and High-end End-to-end to translate broad innovation Innovation technology solutions for science into access ~500 patents automation convenience and reimbursable support services ~150 studies published a year 5

6. Slide 6: Broad network of advanced laboratories

   Broad network of advanced laboratories Boston – Marlborough Cleveland DC Metro – Chantilly, VA Valencia Orange County – San Juan Capistrano (SJC) Memphis Dallas - Lewisville Esoteric Laboratory 6 Confidential | Internal Use Only

7. Slide 7: Strong reputation for global opportunities: Global Diagnostics Network

   Strong reputation for global opportunities: Global Diagnostics Network 7 Confidential | Internal Use Only

8. Slide 8: Four pillars to deliver value and growth through innovation

   Four pillars to deliver value and growth through innovation Science & Service Partnerships & Innovation Expertise Experience Acquisitions Actionable | Accessible | Reimbursable 8 Confidential | Internal Use Only

9. Slide 9: Closing crucial gaps in product innovation

   Closing crucial gaps in product innovation Since late 2016 … Internal R&D Partners Acquisitions  Carrier Screening  Liquid Biopsy  Community Cancer  Exome Sequencing-  Artificial Intelligence  Fertility Newborn  Digital Pathology  Cardio-metabolic  Alzheimer’s Disease  Consumer Genetics 

10. Slide 10: Developing enhanced services to meet amplified expectations

    Developing enhanced services to meet amplified expectations Q: Am I covered? Q: How much will Q: What do my it cost? results mean? A: Pre-authorization A: Out of pocket price A: Genetic counseling estimation services 10 Confidential | Internal Use Only

11. Slide 11: Partnering to seize market opportunities

    Partnering to seize market opportunities Early stage and pharma Research • ~50 companion diagnostics • PROMISE – Multiple myeloma • Q2 joint venture • BFOR – Breast Cancer / BRCA • Dementia Discovery Fund • One Brave Idea – Heart Disease Market development • Community Oncology • Tuberculosis screeni

12. Slide 12: The full complement for multiple myeloma

    The full complement for multiple myeloma We are delivering leading solutions across the patient journey PCP Hematologist Screening Diagnosis Prognosis Treatment Monitoring Early Genetic Diagnostic Digital Pathology MyPRS Genomic MRD Daratumumab- Prescription Drug Risk Assessment Pathways Profiling F

13. Slide 13: Accompanying women on their healthcare journey

    Accompanying women on their healthcare journey Pregnancy Noninvasive Post-natal / Pre-conception prenatal screening Fertility newborn ReproSource Carrier Out-of-pocket Exome screening estimates sequencing Patient-facing genetic counseling Well Woman Adolescence to post-menopause Health & Wellness –

14. Slide 14: Advanced Diagnostics delivers value across our core strategies

    Advanced Diagnostics delivers value across our core strategies M&A Health Systems Consumer Data / Innovation Services provide Inherited Population Health hospital labs clinical value that Genetics and the Bioinformatics can’t provide payers reimburse basis of AI-infused data Precision Health Genetic

15. Slide 15: Key takeaways

    Key takeaways  Precision medicine and Advanced Diagnostics represent strong growth potential  We lead today, we’re profitable, and our strengths position us to win more  Expanded health plan access will build momentum to accelerate profitable growth 15 Confidential | Internal Use Only

Quest Diagnostics — Investor Day (November 2018) on 6ix